Signal-processing concepts—especially sampling rate, Nyquist limits, saturation kinetics, and time–frequency trade-offs—map almost one-to-one onto the peptide-pharmacology problems of how often to dose and how far to push receptor occupancy. The excerpts converge on four practical lessons.
1. Treat the circadian/circannual peptide rhythm as the “carrier wave” you must sample, not ignore.
Handbook of Biologically Active Peptides repeatedly shows that identical doses of gastrin, prolactin, TRH or atrial-natriuretic peptide can switch from effective to inactive—or even reverse their physiologic sign—when the circadian phase is shifted by only a few hours. Fitting a cosine curve to the endogenous baseline (the chronome) before choosing the dosing interval prevents “aliasing” the true signal: giving a bolus every 12 h when the native peptide peaks every 24 h drives the system at a beat frequency that cancels the effect (excerpts 3, 4, 20, 21, 33). The Nyquist rule therefore translates to “dose at least twice within the shortest physiologic period you care about,” otherwise you undershoot and mis-read efficacy.
2. Receptor saturation is a non-linear, often negatively cooperative, amplifier—exactly like a radio front-end that clips.
Lefkowitz’s radioligand work (excerpts 24, 25, 31, 32) demonstrates that most peptide receptors do not obey classic Michaelis-Menten hyperbolae; Scatchard plots are curvilinear, indicating two affinity states or rapid exchange between bound and free ligand. The practical corollary is that pushing the dose ever higher yields diminishing increments in occupancy and can accelerate dissociation of already-bound molecules—analogous to inter-modulation distortion in an overdriven circuit. Once ≥70 % of the high-affinity state is occupied, further ligand not only adds little signal but can shorten the half-life of the drug–receptor complex, shortening the biologic effect even though the plasma concentration keeps rising.
3. The native half-life sets the fundamental frequency; synthetic analogues are “matched filters” engineered to avoid aliasing.
Seeds (excerpt 14) stresses that most endogenous peptides are “signaled, do their job, and exit” within minutes. If the therapeutic goal is to recreate the natural pulse train, the exogenous peptide must be cleared or inactivated on the same time scale; otherwise the system adapts by receptor down-regulation—equivalent to a DC offset that saturates the amplifier. Chemically modified analogues (lipidation, cyclization, D-amino-acid substitution) lengthen the half-life so that a once-daily or once-weekly injection can still deliver a peak-to-trough ratio that the cell interprets as pulsatile rather than chronic (Castanho & Neves, excerpt 19). The design rule borrowed from matched-filter theory is: make the impulse-response of the drug no wider than the physiologic pulse you want to mimic, or fold the dose into multiple micro-boluses that reconstruct the desired spectrum.
4. Microdialysis and MS profiling act like a high-sample-rate ADC, revealing when the “digitized” peptide signal is clipped or under-sampled.
Handbook chapters on microdialysis (excerpts 22, 23, 35, 36) show that extracellular peptide concentrations can rise and fall within 3–5 min during a behavior. If dosing is spaced hours apart, the troughs fall to zero and the receptors see a square-wave that bears no resemblance to the native spike train; gene expression programs switch from physiological to stress-like. Real-time MS feedback therefore allows closed-loop adjustment of infusion rate so that the exogenous input plus the endogenous residual stay inside the linear portion of the occupancy curve—never touching the saturation ceiling where negative cooperativity begins.
Surprising, actionable finding
The most counter-intuitive insight is that “more frequent, smaller” is not always better: when the receptor exhibits negative cooperativity, micro-dosing every few minutes can keep the low-affinity state permanently occupied, producing tachyphylaxis faster than a single large pulse that is allowed to wash out (Lefkowitz excerpts 31, 32). The optimal interval is the one that lets high-affinity sites reset to baseline before the next bolus—typically 4–6 times the dissociation t½ of the high-affinity state, not the plasma t½ of the peptide.
Critical gaps
None of the books provide a unified algorithm that translates in-vitro binding cooperativity constants into a clinical dosing clock. Handbook chapters acknowledge that circannual and circasemiseptan rhythms modulate cancer risk (excerpts 9, 10, 33, 34), but give no method to fold those ultra-low frequencies into everyday subcutaneous protocols. Finally, although Seeds and Castanho describe longer-lasting analogues, none quantify how much the prolonged tail must be truncated to avoid receptor “DC-offset” down-regulation.
Signal-processing theory tells us to dose peptides at a frequency that oversamples the fastest physiologic rhythm you want to preserve, keep peak receptor occupancy below the negatively cooperative saturation knee (≈70 % of high-affinity sites), and let the ligand wash out before the next pulse—anything else aliases the endogenous signal or clips the receptor amplifier.
References
- Handbook of Biologically Active Peptides
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
- Receptor Regulations — Robert J Lefkowitz